NCT00848055 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

October 31, 2010

Conditions

Psoriasis

Interventions

DRUG

AbGn168 intravenous infusion

single dose intravenous infusion

DRUG

AbGn168 intravenous infusion

single dose intravenous infusion

DRUG

AbGn168 intravenous infusion

single dose intravenous infusion

DRUG

AbGn168 intravenous infusion

single dose intravenous infusion

DRUG

AbGn168 intravenous infusion

single dose intravenous infusion

DRUG

AbGn168 intravenous infusion

single dose intravenous infusion

DRUG

AbGn168 intravenous infusion

single dose intravenous infusion

DRUG

AbGn168 subcutaneous injection

single dose subcutaneous injection

Trial Locations (7)

1240.1.05 Boehringer Ingelheim Investigational Site, Boise

1240.1.06 Boehringer Ingelheim Investigational Site, Evansville

1240.1.04 Boehringer Ingelheim Investigational Site, Baltimore

1240.1.02 Boehringer Ingelheim Investigational Site, Boston

1240.1.01 Boehringer Ingelheim Investigational Site, New York

1240.1.03 Boehringer Ingelheim Investigational Site, Dallas

1240.1.7 Boehringer Ingelheim Investigational Site, Berlin